São Paulo – Brazil’s Health Minister, Alexandre Padilha, met on Thursday afternoon (7) with the Pharmaceutical Research Industry Association (Interfarma), which represents international companies in Brazil. The meeting took place during the entity’s Board of Directors meeting in São Paulo and aimed to discuss industry demands and government initiatives.

“We talked about how this partnership will help Brazil occupy an increasingly prominent position in production, technological innovation, and access to medicines here in our country,” said the minister.

This was not Padilha’s first meeting with the pharmaceutical industry. On May 7, the minister had already met with various organizations at a sector dinner in Brasília. Also, on Wednesday (6), the government representative took part in the Health Forum, an event organized by Esfera Brasil in partnership with EMS.

Padilha highlighted that one of the main topics discussed was the new regulatory framework for clinical research, an instrument that could boost the sector and bring more innovation, aligned with the Health Economic-Industrial Complex (CEIS) policy. However, the sector is still awaiting regulation.

Also discussed was the reorganization of the Brazilian Health Regulatory Agency (Anvisa) to speed up product approvals. In addition, the minister pointed out that the pricing of incremental innovation — a discussion within the scope of the Drug Market Regulation Chamber (CMED), which was under public consultation until July 10 — was another topic on the agenda. The “Agora Tem Especialistas” program was also mentioned because, according to Padilha, it creates new demand for medicines.

Source: Futuro da Saúde

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com.